top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hCCR8 mice
Strain Name
C57BL/6-Ccr8tm1(CCR8)Bcgen/Bcgen
Common Name  B-hCCR8 mice
Background C57BL/6 Catalog number  110096
Related Genes 

C-C motif chemokine receptor 8; CY6; TER1; CCR-8; 

CKRL1; CDw198; CMKBR8; GPRCY6; CMKBRL2; CC-CKR-8

NCBI Gene ID
12776

mRNA expression analysis


from clipboard


Strain specific analysis of CCR8 gene expression in C57BL/6 and B-hCCR8 mice by RT-PCR. Mouse Ccr8 mRNA was detectable in thymocytes of wild-type mice (+/+) . Human CCR8 mRNA was detectable only in homozygous B-hCCR8 mice (H/H) but not in wild-type mice (+/+). 


Protein expression analysis


from clipboard


Strain specific analysis of CCR8 gene expression in B-hCCR8 mice by FACS. MC38 cells were inoculated into wild-type C57BL/6 (+/+) and homozygous B-hCCR8 mice (H/H). Tumors were harvested at the endpoint of experiment, and the TILs were analyzed by flow cytometry. Human CCR8 was both detectable on CD4+ T cells and Treg cells in tumors of homozygous B-hCCR8 mice, and mouse CCR8 was detectable only in wild-type mice.

Leukocytes cell subpopulation and CCR8 expression analysis in spleen, thymus, 

and blood of B-hCCR8 mice (non-tumor bearing)


Protein expression analysis of mouse and human CCR8 in spleen

from clipboard


Strain specific analysis of CCR8 gene expression in B-hCCR8 mice by FACS. Spleen was isolated from the mice, and analyzed by flow cytometry. Human and mouse CCR8 were not expressed neither in splenocytes of wild-type mice nor B-hCCR8 mice separately.

Protein expression analysis of mouse and human CCR8 in thymus

from clipboard

Strain specific analysis of CCR8 gene expression in B-hCCR8 mice by FACS. Thymus was isolated from the mice, and analyzed by flow cytometry. Human and mouse CCR8 were not expressed neither in thymocytes of wild-type mice nor B-hCCR8 mice separately.


Protein expression analysis of mouse and human CCR8 in blood

from clipboard


Strain specific analysis of CCR8 gene expression in B-hCCR8 mice by FACS. Blood were harvested from the mice, and analyzed by flow cytometry. Human and mouse CCR8 were not expressed neither in blood cells of wild-type mice nor B-hCCR8 mice separately.

Analysis of leukocytes cell subpopulation in B-hCCR8 mice

from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hCCR8 mice (n=3, 8-week-old). Flow cytometry analysis of the splenocytes were performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cell, B cell, NK cell, monocyte, dendritic cell, granulocyte and macrophage in homozygous B-hCCR8 mice were similar to those in the C57BL/6 mice, demonstrating that CCR8 humanized does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SEM.

from clipboard


Analysis of thymocytes leukocyte subpopulations by FACS. Thymocytes were isolated from female C57BL/6 and B-hCCR8 mice (n=3, 8-week-old). Flow cytometry analysis of the thymocytes were performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cell, B cell, NK cell, monocyte, dendritic cell, granulocyte and macrophage in homozygous B-hCCR8 mice were similar to those in the C57BL/6 mice, demonstrating that CCR8 humanized does not change the overall development, differentiation or distribution of these cell types in thymus. Values are expressed as mean ± SEM.

from clipboard


Analysis of blood leukocyte subpopulations by FACS. Blood were isolated from female C57BL/6 and B-hCCR8 mice (n=3, 8-week-old). Flow cytometry analysis of the blood cells were performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cell, B cell, NK cell, monocyte, dendritic cell, granulocyte and macrophage in homozygous B-hCCR8 mice were similar to those in the C57BL/6 mice, demonstrating that CCR8 humanized does not change the overall development, differentiation or distribution of these cell types in blood. Values are expressed as mean ± SEM.

Analysis of T cell subpopulation in B-hCCR8 mice

from clipboard

from clipboard


Analysis of T cell subpopulation in spleen, thymus and blood.The lymphocytes were isolated from spleen, thymus and blood in C57BL/6 and B-hCCR8 mice (n=3, 8-week-old). The proportion of T cells subpopulation was tested by flow cytometry. There were no differences between C57BL/6 and B-hCCR8 mice, demonstrating that humanized of CCR8 does not change the overall development, differentiation or distribution of these T cell subtypes. Values are expressed as mean ± SEM.

Establishment of mouse MC38 colon cancer model based on B-hCCR8 mice and analysis leukocyte subpopulations and CCR8 expression of tumor, spleen, and blood.

Gating strategy

from clipboard

Protein expression analysis of mouse and human CCR8 in tumor


from clipboard


Strain specific analysis of CCR8 gene expression in B-hCCR8 mice by FACS. TILs were harvested at the endpoint of experiment, and analyzed by flow cytometry. Human CCR8 was both detectable on CD4+ T cells and Treg cells in tumors of homozygous B-hCCR8 mice, and mouse CCR8 was detectable in wild-type mice.

Protein expression analysis of mouse and human CCR8 in spleen

from clipboard


Strain specific analysis of CCR8 gene expression in B-hCCR8 mice by FACS. Splenocytes were harvested at the endpoint of experiment, and analyzed by flow cytometry. Mouse CCR8 was slightly expressed in Treg cells in spleen of wild-type mice, but human CCR8 was not detectable in homozygous B-hCCR8 mice. Because the CCR8 expression was low in the spleen, so maybe the CCR8 expressed much lower in the spleen of homozygous B-hCCR8 mice that we can’t detect it, or the antibody dose we used in this experiment is not saturated.

Protein expression analysis of mouse and human CCR8 in blood

from clipboard


Strain specific analysis of CCR8 gene expression in B-hCCR8 mice by FACS. Blood cells were harvested at the endpoint of experiment, and analyzed by flow cytometry. Human and mouse CCR8 were not expressed neither in blood cells of wild-type mice nor human CCR8 separately.

Summary for protein expression

from clipboard


Strain specific analysis of CCR8 gene expression in B-hCCR8 mice by FACS. Human CCR8 was both detectable on CD4+ T cells and Treg cells in tumors of homozygous B-hCCR8 mice, but not in splenocytes and blood cells. Mouse CCR8 was detectable in tumors and slightly expressed in splenocytes of wild-type mice, but not in blood cells.

Analysis of leukocytes cell subpopulation in B-hCCR8 mice bearing MC38 tumors

from clipboard


Analysis of leukocyte subpopulations of tumor, spleen and blood by FACS.
Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hCCR8 mice (female, 8 week-old, n=3). Tumors, splenocytes and blood cells were harvested at the endpoint of the experiment (tumor volumes~1000mm3), and flow cytometry analysis was performed to assess leukocyte subpopulations. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. Values are expressed as mean ± SEM.

Complete blood count and blood chemistry

Blood routine test in B-hCCR8 mice

from clipboard


Complete blood count (CBC). Blood from female C57BL/6 and B-hCCR8 mice (n=8, 9 week-old) was collected and analyzed for CBC. The measurements of B-hCCR8 mice were similar to that in C57BL/6 mice, indicating that humanization does not change blood cell composition and morphology. Values are expressed as mean ± SEM.

Blood chemistry of B-hCCR8 mice

from clipboard





Blood chemistry tests of B-hCCR8 mice. Serum from the C57BL/6 and B-hCCR8 mice (n=8, 9 week-old) was collected and analyzed for levels of indicators. The measurements of B-hCCR8 mice were similar to that in C57BL/6 mice, indicating that humanization does not change the health of related tissues, such as liver. Values are expressed as mean ± SEM.

In vivo efficacious of anti-human CCR8 antibody



In vivo efficacy of anti-human CCR8 antibody


from clipboard


Antitumor activity of anti-human CCR8 antibody in B-hCCR8 mice bearing MC38 cells. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hCCR8 mice (female, 7 week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human CCR8 antibodies (in house). (A) Tumor growth curve. (B) Body weight changes during treatment. As shown, anti-human CCR8 antibodies were efficacious in controlling tumor growth in B-hCCR8 mice. B-hCCR8 mice provide a powerful preclinical model for in vivo evaluation of anti-human CCR8 antibodies. Values are expressed as mean ± SEM.


from clipboard

Antitumor activity of anti-human CCR8 antibody in B-hCCR8 mice. (A) Anti-human CCR8 antibody get from cooperation company inhibited MC38 tumor growth in B-hCCR8 mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hCCR8 mice (female, 8 week-old, n=7). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human CCR8 antibody. (B) Body weight changes during treatment. As shown in panel A, anti-human CCR8 antibody were efficacious in controlling tumor growth in B-hCCR8 mice. B-hCCR8 mice provide a powerful preclinical model for in vivo evaluation of anti-human CCR8 antibody. Values are expressed as mean ± SEM.


Tumor infiltrates lymphocytes analysis



from clipboard

Analysis of tumor infiltrates lymphocytes by FACS.TILs were harvested at the endpoint of the experiment and flow cytometry analysis was performed to assess the leukocyte subpopulations. The percent of CCR8+ Treg cells were significant decrease in anti-human CCR8 antibody treatment group (G2, G4), and the ratio CD8+ T cells to Treg cells increased significantly in G2, but not in G4. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001)